Chemistry: analytical and immunological testing – Peptide – protein or amino acid – Glycoproteins
Reexamination Certificate
2008-07-01
2011-10-04
Kim, Vickie (Department: 1777)
Chemistry: analytical and immunological testing
Peptide, protein or amino acid
Glycoproteins
C436S064000, C436S086000, C436S171000
Reexamination Certificate
active
08030085
ABSTRACT:
The present invention provides a method for accurately discriminating between prostate carcinoma and benign prostatic hyperplasia based on a glycan structure of prostate specific antigen (PSA). The method of the present invention includes the steps of: purifying PSA from a sample derived from a subject; preparing a PSA derivative from the PSA; labeling the PSA derivative; and analyzing the labeled PSA derivative by the mass spectrometry method, in which the subject is identified as having prostate carcinoma when the ratio of the signal intensity of fucose-unbound glycan to the signal intensity of fucose-bound glycan in the labeled PSA derivative is greater than 1.0, and identified as having benign prostatic hyperplasia when the ratio is 1.0 or less.
REFERENCES:
patent: 2004/0147033 (2004-07-01), Shriver et al.
patent: 2008/0071148 (2008-03-01), Bosques et al.
patent: 2008/0138908 (2008-06-01), Amano
patent: 2 361 060 (2001-10-01), None
patent: A-2000-514919 (2000-11-01), None
patent: A-2006-515927 (2006-06-01), None
patent: WO 98/00711 (1998-01-01), None
patent: A-2002-055108 (2002-02-01), None
patent: WO 2004/060915 (2004-07-01), None
patent: WO 2004/066808 (2004-08-01), None
Abstract of: Stamey et al., “Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate,” The New England Journal of Medicine, vol. 317, No. 15, pp. 909-916; 1987.
Catalona et al., “Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer from Benign Prostatic Disease: A Prospective Multicenter Clinical Trial,” Journal of American Medical Association; vol. 279, No. 19, 1542-1547; 1998.
Sumi et al., “Serial lectin affinity chromatography demonstrates altered asparagine-linked sugar-chain structures of prostate-specific antigen in human prostate carcinoma,” Journal Chromatography B, vol. 727, pp. 9-14; 1999.
Tabares et al., “Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA,” Glycobiology; vol. 16, No. 2, pp. 132-145; 2006.
Peter et al., “Purification of Prostate-Specific Antigen from Human Serum by Indirect Immunosorption and Elution with a Hapten,” Analytical Biochemistry, vol. 273, No. 1, pp. 98-104, 1999.
Kawinski et al., “Thiophilic Interaction Chromatography Facilitates Detection of Various Molecular Complexes of Prostate-Specific Antigen in Biological Fluids,” The Prostate, vol. 50, No. 3, pp. 145-153, 2002.
Bindukumar et al., “Two step procedure for purification of enzymatically active prostate-specific antigen from semincal plasma,” Journal of Chromatography B, vol. 813, No. 1-2, pp. 113-120, 2004.
Zhang et al., “Purification and Characterization of Different Molecular Forms of Prostate-Specific Antigen in Human Seminal Fluid,” Clinical Chemistry., vol. 41, No. 11, pp. 1567-1573, 1995.
Okada et al., “Structural characteristics of the N-glycans of two isoforms of prostate-specific antigens purified from human seminal fluid,” Biochimica ct Biophysica Acta, vol. 1525, No. 1-2, pp. 149-160, 2001.
Peracaula et al., “Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins,” Glycobiology, vol. 13, No. 6, pp. 457-470, 2003.
Tajiri et al., “Oligosaccharide profiles of the prostate specific antigen in free and complexed forms from prostate cancer patient serum and in seminal plasma: a glycopeptide approach,” Glycobiology Advance Access, pp. 1-20, Oct. 23, 2007.
Prakash S. et al., “Glycotyping of Prostate Specific Antigen,” Oxford University Press, 2000, pp. 173-176, vol. 10 No. 2.
Jun. 9, 2010 European Search Report issued in EP 08 77 7915.
Amano Junko
Hirano Kiyoko
Sugimoto Ichiro
Gerido Dwan A
Kim Vickie
Oliff & Berridg,e PLC
The Noguchi Institute
LandOfFree
Method for discriminating between prostatic cancer and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for discriminating between prostatic cancer and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for discriminating between prostatic cancer and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4260154